Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
about
CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune DysregulationMarijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Endocannabinoid system in neurodegenerative disorders.URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors.
P2860
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
@en
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
@nl
type
label
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
@en
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
@nl
prefLabel
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
@en
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
@nl
P2093
P50
P1476
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease
@en
P2093
Cecilia J Hillard
Diana Fernández-Suárez
José A López-Moreno
Marta Celorrio
Rafael Maldonado
P304
P356
10.1016/J.BBI.2016.06.010
P50
P577
2016-06-16T00:00:00Z